Floatz logo

LENVATINIB

Nab-paclitaxel

Qilu Hospital of Shandong UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Nab-paclitaxel cohort.

Asset / SponsorPhaseRating
Carboplatin
Hebei Medical University Fourth Hospital
Phase 2CCC
Epirubicin
Hebei Medical University Fourth Hospital
Phase 2CCC
S-1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2CCC
Capecitabine
Hebei Medical University Fourth Hospital
Phase 2CCC
Tislelizumab
Qilu Hospital of Shandong University
Phase 2CCC

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →